,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,KNG1,"BDK, BK, KNG",ENSG00000113889,Kininogen 1,3,186717276-186743954,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA001616, HPA001645, CAB009809",Enhanced,,,,Liver cancer:1.28e-6 (favourable),Tissue enriched,Group enriched,994,kidney: 522.4;liver: 1864.6,rectum: 1.2,Cell line enhanced,,CACO-2: 1.5;Hep G2: 1.2;RH-30: 1.3
1,UGT1A9,"HLUGP4, LUGP4, UGT1AI",ENSG00000241119,UDP glucuronosyltransferase family 1 member A9,2,233671853-233773300,"Cancer-related genes, Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Renal cancer:5.04e-5 (unfavourable),Group enriched,Group enriched,592,kidney: 465.5;liver: 93.3,"cerebral cortex,colon: 0.4",Cell line enhanced,,A549: 1.2
2,ACSM2A,"A-923A4.1, ACSM2, MGC150530",ENSG00000183747,Acyl-CoA synthetase medium-chain family member 2A,16,20451461-20487667,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA057699,Supported,,,,Liver cancer:1.41e-5 (favourable),Group enriched,Group enriched,580,kidney: 285.2;liver: 185.7,cerebral cortex: 0.4,Cell line enhanced,,Hep G2: 1.3
3,HAO2,"GIG16, HAOX2",ENSG00000116882,Hydroxyacid oxidase 2,1,119368779-119394130,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,Renal cancer:4.92e-4 (favourable),Group enriched,Group enriched,300,kidney: 317.5;liver: 219.8,"adrenal gland,breast: 0.8",Not detected,,
4,BHMT,BHMT1,ENSG00000145692,Betaine--homocysteine S-methyltransferase,5,79111779-79132290,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038285, HPA058310",Enhanced,,Supported,Cytosol,Liver cancer:7.32e-4 (favourable),Tissue enhanced,Group enriched,225,kidney: 788.8;liver: 563.6,urinary bladder: 3.0,Cell line enhanced,,Hep G2: 2.4;NTERA-2: 1.4;SCLC-21H: 1.1
5,CYP4A11,"CYP4A2, CYP4AII",ENSG00000187048,Cytochrome P450 family 4 subfamily A member 11,1,46929177-46941484,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,183,kidney: 232.3;liver: 448.3,gallbladder: 1.8,Not detected,,
6,ACSM2B,"ACSM2, HXMA, HYST1046",ENSG00000066813,Acyl-CoA synthetase medium-chain family member 2B,16,20536226-20576427,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA057699,Supported,,,,Liver cancer:3.31e-4 (favourable),Group enriched,Group enriched,136,kidney: 426.7;liver: 262.0,thyroid gland: 2.5,Cell line enhanced,,AF22: 2.8;Hep G2: 3.7
7,AQP2,,ENSG00000167580,Aquaporin 2,12,49950741-49958881,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA046834,Enhanced,,,,,Group enriched,Group enriched,132,kidney: 435.9;seminal vesicle: 302.5,testis: 2.8,Cell line enhanced,,EFO-21: 3.0;HMC-1: 1.7
8,SLC22A11,OAT4,ENSG00000168065,Solute carrier family 22 member 11,11,64555626-64572875,"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA026076,Approved,,,,Renal cancer:3.68e-5 (favourable),Group enriched,Group enriched,114,epididymis: 10.0;kidney: 26.0;placenta: 44.8,seminal vesicle: 0.2,Cell line enhanced,,BEWO: 1.2
9,PRODH2,HSPOX1,ENSG00000250799,Proline dehydrogenase 2,19,35799988-35813299,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA051287,Approved,,Supported,Nucleoplasm<br>Cytosol,,Group enriched,Group enriched,96,kidney: 132.8;liver: 45.1,testis: 0.9,Cell line enriched,14.0,Hep G2: 21.4
10,HPD,"4-HPPD, 4HPPD, GLOD3, PPD",ENSG00000158104,4-hydroxyphenylpyruvate dioxygenase,12,121839527-121863596,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038321, HPA038322",Enhanced,,Uncertain,Nuclear speckles,,Tissue enriched,Group enriched,86,kidney: 529.9;liver: 1293.2,seminal vesicle: 10.5,Cell line enriched,24.0,Hep G2: 349.1
11,SLC22A7,"NLT, OAT2",ENSG00000137204,Solute carrier family 22 member 7,6,43295694-43305538,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA030220,Approved,,,,"Liver cancer:5.48e-6 (favourable), Renal cancer:8.98e-4 (favourable)",Tissue enriched,Group enriched,73,kidney: 50.3;liver: 167.8,testis: 1.4,Cell line enriched,14.0,Hep G2: 6.7
12,POU3F3,"BRN1, OTF8",ENSG00000198914,POU class 3 homeobox 3,2,104855511-104858574,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA052792, HPA056039, HPA067151",Approved,,Enhanced,Nucleus,Endometrial cancer:4.26e-5 (unfavourable),Group enriched,Group enriched,45,cerebral cortex: 43.9;epididymis: 46.3;kidney: 36.6;seminal vesicle: 23.2,skin: 0.8,Group enriched,5.0,AF22: 58.4;AN3-CA: 52.7;HEK93: 20.3;RPTEC TERT1: 50.7;SH-SY5Y: 19.7
13,DAO,DAMOX,ENSG00000110887,D-amino acid oxidase,12,108858932-108901043,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA038653, HPA038654",Enhanced,,,,Renal cancer:4.11e-4 (favourable),Tissue enriched,Group enriched,36,kidney: 89.8;liver: 74.1,rectum: 2.2,Not detected,,
14,DUSP9,"MKP-4, MKP4",ENSG00000130829,Dual specificity phosphatase 9,X,153642492-153651326,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA003336,Enhanced,,Approved,Endoplasmic reticulum,Endometrial cancer:1.60e-4 (unfavourable),Mixed,Group enriched,35,kidney: 29.0;placenta: 103.3,testis: 1.8,Cell line enriched,6.0,Hep G2: 251.7
15,AGXT2,AGT2,ENSG00000113492,Alanine--glyoxylate aminotransferase 2,5,34998101-35048135,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037382,Enhanced,,,,Renal cancer:7.47e-4 (favourable),Group enriched,Group enriched,33,kidney: 197.9;liver: 59.3,small intestine: 3.9,Not detected,,
16,SLC10A2,"ASBT, ISBT",ENSG00000125255,Solute carrier family 10 member 2,13,103043998-103066846,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA004795,Approved,,,,Renal cancer:5.78e-5 (favourable),Tissue enriched,Group enriched,31,duodenum: 21.0;kidney: 15.4;small intestine: 51.4,gallbladder: 0.9,Not detected,,
17,DIO1,TXDI1,ENSG00000211452,Iodothyronine deiodinase 1,1,53891239-53911086,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,Thyroid cancer:5.44e-4 (unfavourable),Group enriched,Group enriched,30,kidney: 147.5;liver: 94.9;thyroid gland: 434.9,fallopian tube: 7.5,Group enriched,20.0,Hep G2: 23.0;SK-BR-3: 59.3
18,ALDH8A1,ALDH12,ENSG00000118514,Aldehyde dehydrogenase 8 family member A1,6,134917390-134950122,Predicted intracellular proteins,Evidence at protein level,"HPA026292, HPA055414",Enhanced,,Supported,Centrosome,Renal cancer:9.87e-4 (favourable),Group enriched,Group enriched,29,kidney: 74.3;liver: 127.7,cerebral cortex: 3.4,Mixed,,
19,ERICH4,"C19orf69, LOC100170765",ENSG00000204978,Glutamate rich 4,19,41443158-41444765,Predicted intracellular proteins,Evidence at transcript level,"HPA042632, HPA048484",Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Group enriched,27,duodenum: 42.8;kidney: 16.3;small intestine: 42.9,lung: 1.2,Group enriched,13.0,CACO-2: 2.1;Hep G2: 4.2;THP-1: 1.1
20,SLC36A2,"PAT2, TRAMD1, tramdorin",ENSG00000186335,Solute carrier family 36 member 2,5,151314978-151347590,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA044002, HPA062229",Enhanced,,,,,Tissue enriched,Group enriched,27,kidney: 67.7;skeletal muscle: 28.0,testis: 1.7,Not detected,,
21,SLC28A1,CNT1,ENSG00000156222,Solute carrier family 28 member 1,15,84884654-84945796,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA019551,Enhanced,,,,,Group enriched,Group enriched,26,duodenum: 37.9;kidney: 49.4;liver: 35.4;small intestine: 53.6,placenta: 1.7,Not detected,,
22,ALDOB,,ENSG00000136872,"Aldolase, fructose-bisphosphate B",9,101420578-101435823,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002198, CAB020827",Enhanced,,,,,Tissue enriched,Group enriched,23,duodenum: 3705.7;kidney: 6574.8;liver: 5092.2;small intestine: 5611.2,gallbladder: 231.1,Cell line enhanced,,BEWO: 16.8;NB-4: 10.8;RPMI-8226: 13.6;SH-SY5Y: 17.3
23,CLEC18C,MGC34761,ENSG00000157335,C-type lectin domain family 18 member C,16,70173322-70187361,Predicted secreted proteins,Evidence at transcript level,HPA048976,Uncertain,,,,,Tissue enriched,Group enriched,23,kidney: 11.4;testis: 3.6,duodenum: 0.3,Not detected,,
24,UPB1,BUP1,ENSG00000100024,Beta-ureidopropionase 1,22,24494107-24528390,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA000728,Enhanced,,,,Liver cancer:2.30e-7 (favourable),Tissue enriched,Group enriched,23,kidney: 51.2;liver: 161.7,testis: 4.6,Cell line enhanced,,CACO-2: 6.0;NB-4: 1.9;THP-1: 2.7;U-937: 3.5
25,CUBN,"gp280, IFCR, MGA1",ENSG00000107611,Cubilin,10,16823964-17129831,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA004133, HPA043854",Enhanced,,,,Renal cancer:1.12e-4 (favourable),Tissue enriched,Group enriched,22,kidney: 153.7;small intestine: 54.4,thyroid gland: 4.7,Cell line enhanced,,AN3-CA: 14.6;WM-115: 5.9
26,DPYS,DHPase,ENSG00000147647,Dihydropyrimidinase,8,104330324-104467053,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA024785,Enhanced,,,,,Group enriched,Group enriched,22,kidney: 200.4;liver: 246.2,gallbladder: 10.1,Not detected,,
27,PFN3,,ENSG00000196570,Profilin 3,5,177400107-177400636,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Group enriched,21,kidney: 1.0;testis: 3.2,all non-specific tissues: 0.0,Not detected,,
28,SLC6A19,,ENSG00000174358,Solute carrier family 6 member 19,5,1201595-1225117,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA037415, HPA043207",Enhanced,,Approved,Nucleoli,Renal cancer:4.14e-6 (favourable),Tissue enhanced,Group enriched,21,duodenum: 139.5;kidney: 91.8;small intestine: 156.9,rectum: 6.2,Group enriched,6.0,BEWO: 13.7;HEL: 16.3
29,RNF212B,C14orf164,ENSG00000215277,Ring finger protein 212B,14,23185316-23273477,Predicted intracellular proteins,Evidence at transcript level,HPA053574,Uncertain,,,,,Not detected,Group enriched,20,kidney: 27.7;testis: 10.4,thyroid gland: 0.9,Not detected,,
30,FTCD,,ENSG00000160282,Formimidoyltransferase cyclodeaminase,21,46136262-46155567,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020073, HPA030928, HPA030929, HPA036114",Enhanced,,Approved,Plasma membrane<br>Cytosol,"Pancreatic cancer:6.78e-5 (favourable), Liver cancer:1.70e-4 (favourable), Renal cancer:5.78e-4 (favourable)",Tissue enriched,Group enriched,18,kidney: 100.2;liver: 184.7,testis: 7.7,Cell line enriched,24.0,Hep G2: 62.7
31,CYP4A22,,ENSG00000162365,Cytochrome P450 family 4 subfamily A member 22,1,47137435-47149741,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enriched,Group enriched,16,kidney: 33.5;liver: 109.1,epididymis: 4.5,Cell line enriched,5.0,RH-30: 1.2
32,SLC34A3,"FLJ38680, NPTIIc",ENSG00000198569,Solute carrier family 34 member 3,9,137230757-137236554,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA023776,Enhanced,,,,,Mixed,Group enriched,15,kidney: 11.8;small intestine: 9.1,testis: 0.7,Cell line enhanced,,CAPAN-2: 2.9;MCF7: 4.2
33,FAM151A,"C1orf179, MGC27169",ENSG00000162391,Family with sequence similarity 151 member A,1,54609182-54623556,Predicted intracellular proteins,Evidence at protein level,HPA016840,Approved,,Uncertain,Nucleoplasm,Renal cancer:4.09e-5 (favourable),Group enriched,Group enriched,14,kidney: 175.3;small intestine: 66.8,liver: 8.5,Cell line enriched,41.0,CACO-2: 63.5
34,PROZ,PZ,ENSG00000126231,"Protein Z, vitamin K dependent plasma glycoprotein",13,113158654-113172383,"Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA052006,Enhanced,,,,Liver cancer:3.46e-4 (favourable),Tissue enriched,Group enriched,14,kidney: 14.5;liver: 27.4,testis: 1.5,Cell line enhanced,,HaCaT: 1.9;Hep G2: 2.4
35,UPP2,"UDRPASE2, UP2, UPASE2",ENSG00000007001,Uridine phosphorylase 2,2,157876702-158136154,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035225, HPA035226",,,Approved,Nucleus<br>Vesicles<br>Mitochondria,,Tissue enriched,Group enriched,14,kidney: 52.2;liver: 14.3,cerebral cortex: 2.4,Not detected,,
36,GLYATL1,"FLJ34646, MGC15397",ENSG00000166840,Glycine-N-acyltransferase like 1,11,58905398-59043527,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039501,Supported,,Uncertain,Golgi apparatus<br>Cytosol,"Renal cancer:3.03e-5 (favourable), Liver cancer:3.69e-4 (favourable)",Group enriched,Group enriched,13,kidney: 145.2;liver: 298.1,prostate: 17.4,Cell line enhanced,,CACO-2: 1.6;Daudi: 3.5;RPTEC TERT1: 1.2;U-2197: 1.1
37,UGT2B7,UGT2B9,ENSG00000171234,UDP glucuronosyltransferase family 2 member B7,4,69051363-69112987,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA045108,Uncertain,,,,"Colorectal cancer:7.65e-5 (favourable), Renal cancer:3.79e-4 (favourable), Urothelial cancer:5.38e-4 (favourable)",Group enriched,Group enriched,13,kidney: 1326.3;liver: 825.7,fallopian tube: 79.7,Cell line enhanced,,EFO-21: 73.2;RPTEC TERT1: 235.7;U-2197: 40.2
38,CLDN19,,ENSG00000164007,Claudin 19,1,42733093-42740254,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enhanced,Group enriched,12,kidney: 19.7;placenta: 14.5,breast: 1.4,Cell line enhanced,,CACO-2: 2.4;Hep G2: 4.3
39,SLC39A5,,ENSG00000139540,Solute carrier family 39 member 5,12,56230049-56237846,"Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,HPA018423,,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:5.05e-4 (favourable),Tissue enhanced,Group enriched,12,colon: 73.2;duodenum: 240.2;kidney: 115.0;liver: 86.0;pancreas: 53.1;rectum: 48.9;small intestine: 240.4,gallbladder: 10.0,Group enriched,62.0,CACO-2: 33.1;Hep G2: 39.7
40,XPNPEP2,,ENSG00000122121,X-prolyl aminopeptidase 2,X,129738974-129769538,"Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins",Evidence at protein level,"HPA000339, CAB025136, CAB025269",Enhanced,,,,,Group enriched,Group enriched,12,duodenum: 128.1;kidney: 175.9;small intestine: 231.5,liver: 14.3,Cell line enhanced,,ASC diff: 6.9;ASC TERT1: 36.6;HSkMC: 19.4
41,CLDN14,DFNB29,ENSG00000159261,Claudin 14,21,36460621-36576569,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA054707,,,Uncertain,Vesicles,Liver cancer:1.53e-4 (favourable),Tissue enriched,Group enriched,11,kidney: 3.6;liver: 9.5,gallbladder: 0.6,Cell line enriched,18.0,HDLM-2: 205.9
42,DMGDH,,ENSG00000132837,Dimethylglycine dehydrogenase,5,78997606-79236038,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA036441, HPA036442, HPA077849",Enhanced,,Supported,Mitochondria,"Renal cancer:1.17e-5 (favourable), Liver cancer:5.32e-5 (favourable)",Group enriched,Group enriched,11,kidney: 179.1;liver: 146.2,epididymis: 14.9,Cell line enhanced,,BJ hTERT+: 2.9;Hep G2: 5.2
43,KHK,,ENSG00000138030,Ketohexokinase,2,27086747-27100772,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA007040,Enhanced,,Approved,Cytosol,Endometrial cancer:7.62e-8 (unfavourable),Group enriched,Group enriched,11,duodenum: 113.1;kidney: 111.2;liver: 97.3;small intestine: 133.2,cerebral cortex: 10.1,Cell line enhanced,,Hep G2: 32.5
44,RDH8,"PRRDH, SDR28C2",ENSG00000080511,Retinol dehydrogenase 8 (all-trans),19,10013249-10022279,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Group enriched,Group enriched,11,kidney: 1.2;testis: 1.8,appendix: 0.1,Not detected,,
45,ABCC2,"CMOAT, cMRP, DJS, MRP2",ENSG00000023839,ATP binding cassette subfamily C member 2,10,99782732-99852192,"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA004860, CAB037271",Enhanced,,,,Renal cancer:1.93e-5 (unfavourable),Tissue enhanced,Group enriched,10,duodenum: 43.5;gallbladder: 42.7;kidney: 20.9;liver: 67.6;small intestine: 49.5,breast: 4.4,Cell line enhanced,,A549: 203.8;Hep G2: 155.8
46,ACMSD,,ENSG00000153086,Aminocarboxymuconate semialdehyde decarboxylase,2,134838547-134902034,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA010533, HPA011179",Enhanced,,,,Renal cancer:2.39e-4 (favourable),Group enriched,Group enriched,10,kidney: 137.3;liver: 80.2,gallbladder: 10.8,Cell line enriched,16.0,RPTEC TERT1: 19.7
47,ATP6V1B1,"ATP6B1, RTA1B, VATB, Vma2, VPP3",ENSG00000116039,ATPase H+ transporting V1 subunit B1,2,70935882-70965406,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB009523, HPA031847",Enhanced,,Approved,Nucleus<br>Nuclear membrane,,Group enriched,Group enriched,10,"breast: 16.1;cervix, uterine: 47.9;fallopian tube: 21.1;kidney: 64.8;placenta: 27.8;salivary gland: 66.5",skin: 4.2,Group enriched,6.0,BEWO: 20.0;HaCaT: 17.4;SK-BR-3: 34.9
48,CLEC18B,,ENSG00000140839,C-type lectin domain family 18 member B,16,74408270-74421953,Predicted secreted proteins,Evidence at transcript level,HPA048976,Uncertain,,,,Glioma:1.55e-4 (unfavourable),Group enriched,Group enriched,10,kidney: 30.9;testis: 8.1,cerebral cortex: 2.0,Cell line enhanced,,AF22: 1.1;K-562: 2.7
49,GLYAT,"ACGNAT, GAT",ENSG00000149124,Glycine-N-acyltransferase,11,58640426-58731974,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA040251, HPA044094",Enhanced,,,,Renal cancer:1.31e-6 (favourable),Group enriched,Group enriched,10,kidney: 584.9;liver: 355.3,adipose tissue: 47.4,Mixed,,
50,PLA2G12B,PLA2G13,ENSG00000138308,Phospholipase A2 group XIIB,10,72935170-72954778,"Plasma proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"HPA057745, HPA059562",Approved,,Approved,Vesicles,,Tissue enriched,Group enriched,10,duodenum: 35.2;kidney: 19.0;liver: 49.9;small intestine: 45.9,lung: 3.9,Group enriched,6.0,CACO-2: 10.3;Hep G2: 14.2
51,SLC7A9,CSNU3,ENSG00000021488,Solute carrier family 7 member 9,19,32830509-32869766,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA042591,Enhanced,,,,,Group enriched,Group enriched,10,duodenum: 79.0;kidney: 70.1;small intestine: 123.5,liver: 8.9,Group enriched,20.0,BEWO: 3.3;CACO-2: 6.7;Hep G2: 5.4
52,ATP6V0A4,"a4, ATP6N1B, ATP6N2, RDRTA2, RTA1C, RTADR, Stv1, Vph1, VPP2",ENSG00000105929,ATPase H+ transporting V0 subunit a4,7,138706295-138799560,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA018029, HPA064555",Enhanced,,Approved,Cytosol,Renal cancer:1.32e-6 (favourable),Tissue enriched,Group enriched,9,kidney: 69.6;salivary gland: 31.6,breast: 5.5,Cell line enriched,12.0,SK-BR-3: 42.2
53,CCDC150,FLJ39660,ENSG00000144395,Coiled-coil domain containing 150,2,196639554-196763490,Predicted intracellular proteins,Evidence at protein level,"HPA043968, HPA048104",Uncertain,,Approved,Nucleoplasm,,Mixed,Group enriched,9,kidney: 2.6;testis: 8.8,liver: 0.6,Cell line enhanced,,SCLC-21H: 5.2
54,CDHR5,"FLJ20219, MU-PCDH, MUCDHL, MUPCDH",ENSG00000099834,Cadherin related family member 5,11,616565-626078,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA009081, HPA009173, CAB025004",Enhanced,,,,,Group enriched,Group enriched,9,colon: 41.7;duodenum: 82.7;kidney: 23.6;liver: 21.0;rectum: 54.3;small intestine: 64.3,gallbladder: 5.3,Cell line enhanced,,CACO-2: 2.1
55,CLCNKA,hClC-Ka,ENSG00000186510,Chloride voltage-gated channel Ka,1,16018875-16034050,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA057717,Approved,,,,,Group enriched,Group enriched,9,kidney: 64.2;parathyroid gland: 40.4,thyroid gland: 5.5,Group enriched,11.0,RPMI-8226: 1.3;SK-BR-3: 1.4;U-266/70: 5.7
56,HOXC10,HOX3I,ENSG00000180818,Homeobox C10,12,53985065-53990279,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA053919,Uncertain,,Supported,Nucleoplasm<br>Nuclear bodies,,Mixed,Group enriched,9,kidney: 18.9;skeletal muscle: 40.3;skin: 8.4,breast: 2.5,Cell line enhanced,,AN3-CA: 275.9;T-47d: 95.2
57,LRRC19,FLJ21302,ENSG00000184434,Leucine rich repeat containing 19,9,26993136-27005693,Predicted membrane proteins,Evidence at protein level,,,,,,Renal cancer:7.08e-8 (favourable),Group enriched,Group enriched,9,colon: 35.9;duodenum: 23.7;gallbladder: 9.4;kidney: 45.1;rectum: 35.3;small intestine: 34.7,appendix: 3.5,Not detected,,
58,NXPH2,NPH2,ENSG00000144227,Neurexophilin 2,2,138670772-138780348,Predicted secreted proteins,Evidence at transcript level,HPA034759,Approved,,,,,Mixed,Group enriched,9,cerebral cortex: 5.7;kidney: 5.0;ovary: 14.0,endometrium: 0.9,Cell line enhanced,,AF22: 3.8;SCLC-21H: 1.7;SiHa: 4.0;U-2 OS: 6.3;U-251 MG: 1.7
59,RIDA,"HRSP12, P14.5, PSP, UK114",ENSG00000132541,Reactive intermediate imine deaminase A homolog,8,98102344-98117241,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA022856, HPA023489",Enhanced,,,,Liver cancer:9.61e-6 (favourable),Expressed in all,Group enriched,9,kidney: 454.6;liver: 698.7,cerebral cortex: 62.3,Expressed in all,,
60,SMTNL2,FLJ42461,ENSG00000188176,Smoothelin like 2,17,4583999-4608319,Predicted intracellular proteins,Evidence at protein level,,,,,,Renal cancer:1.28e-4 (favourable),Tissue enhanced,Group enriched,9,kidney: 26.8;skeletal muscle: 133.8,fallopian tube: 9.0,Group enriched,7.0,CACO-2: 40.8;SCLC-21H: 13.5
61,TMEM213,,ENSG00000214128,Transmembrane protein 213,7,138797952-138838101,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054059,Enhanced,,,,Renal cancer:5.54e-7 (favourable),Tissue enriched,Group enriched,9,kidney: 80.7;salivary gland: 22.6,breast: 5.7,Not detected,,
62,C5orf67,,ENSG00000225940,Chromosome 5 open reading frame 67,5,56511567-56606232,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Group enriched,8,epididymis: 19.8;kidney: 9.4,thyroid gland: 1.9,Group enriched,7.0,CACO-2: 1.7;EFO-21: 5.3;U-266/70: 4.8
63,CDH16,,ENSG00000166589,Cadherin 16,16,66908122-66918984,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB013526, HPA036260",Enhanced,,,,Renal cancer:1.02e-7 (favourable),Tissue enriched,Group enriched,8,kidney: 231.3;thyroid gland: 58.0,fallopian tube: 17.2,Cell line enriched,78.0,RPTEC TERT1: 163.7
64,CLRN3,"MGC32871, TMEM12, USH3AL1",ENSG00000180745,Clarin 3,10,127877841-127892947,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA014482,Approved,,,,Stomach cancer:8.98e-4 (favourable),Group enriched,Group enriched,8,colon: 69.9;duodenum: 73.3;gallbladder: 23.6;kidney: 44.3;liver: 40.4;rectum: 76.3;small intestine: 97.5,appendix: 7.2,Cell line enriched,6.0,CACO-2: 1.9
65,KCNJ16,"BIR9, Kir5.1",ENSG00000153822,Potassium voltage-gated channel subfamily J member 16,17,70053429-70135608,"Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA059563,Approved,,Uncertain,Vesicles,"Renal cancer:9.61e-7 (favourable), Thyroid cancer:6.58e-4 (favourable)",Group enriched,Group enriched,8,kidney: 209.1;parathyroid gland: 269.7;thyroid gland: 235.1,seminal vesicle: 31.5,Cell line enriched,18.0,RPTEC TERT1: 211.8
66,RP11-397G17.1,,ENSG00000226733,,6,50093616-50181007,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Group enriched,Group enriched,8,epididymis: 136.0;kidney: 50.9,liver: 12.3,Not detected,,
67,SMIM24,"C19orf77, HSPC323",ENSG00000095932,Small integral membrane protein 24,19,3473986-3480542,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA045046, HPA056027",Enhanced,,Approved,Nucleoplasm<br>Cytosol,Renal cancer:4.13e-10 (favourable),Tissue enhanced,Group enriched,8,duodenum: 758.8;epididymis: 1928.7;kidney: 835.9;small intestine: 682.3,stomach: 140.0,Group enriched,8.0,CACO-2: 128.5;HEL: 66.3;Hep G2: 79.7;MOLT-4: 90.8;REH: 56.0;U-937: 68.2
68,AP000322.53,,ENSG00000243627,,21,34418715-34423966,Predicted membrane proteins,Evidence at transcript level,HPA029085,Uncertain,,,,,Not detected,Group enriched,7,breast: 1.5;fallopian tube: 1.4;kidney: 4.3,skin: 0.3,Not detected,,
69,CH507-396I9.3,,ENSG00000278961,,21,7788703-7793954,Predicted membrane proteins,Evidence at transcript level,HPA029085,Uncertain,,,,,Not detected,Group enriched,7,breast: 1.5;fallopian tube: 1.4;kidney: 4.3,skin: 0.3,Not detected,,
70,CLEC18A,MRCL,ENSG00000157322,C-type lectin domain family 18 member A,16,69950705-69964452,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA048976,Uncertain,,,,,Tissue enriched,Group enriched,7,kidney: 15.7;testis: 3.7,adrenal gland: 1.3,Not detected,,
71,EHHADH,ECHD,ENSG00000113790,Enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase,3,185190624-185281990,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA036401, HPA042021",Enhanced,,,,Renal cancer:1.28e-5 (favourable),Group enriched,Group enriched,7,kidney: 148.6;liver: 173.1,duodenum: 21.4,Mixed,,
72,ESRRB,"DFNB35, ERR2, ERRb, ERRbeta, ESRL2, NR3B2",ENSG00000119715,Estrogen related receptor beta,14,76310614-76501841,"Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Mixed,Group enriched,7,heart muscle: 2.3;kidney: 5.2;skeletal muscle: 1.7;stomach: 1.5;testis: 1.4,breast: 0.3,Cell line enhanced,,HMC-1: 1.0;K-562: 3.3;U-266/70: 1.2
73,GCGR,GGR,ENSG00000215644,Glucagon receptor,17,81804132-81814013,"FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA071228,,,Approved,Golgi apparatus,,Tissue enhanced,Group enriched,7,adrenal gland: 6.6;kidney: 8.4;liver: 20.8;parathyroid gland: 8.0,skin: 1.6,Cell line enhanced,,HeLa: 1.2;MCF7: 2.2;SK-BR-3: 1.8;U-87 MG: 2.7
74,PIPOX,LPIPOX,ENSG00000179761,Pipecolic acid and sarcosine oxidase,17,28950513-29057220,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,Pancreatic cancer:1.49e-4 (favourable),Group enriched,Group enriched,7,kidney: 137.9;liver: 235.9,epididymis: 26.0,Group enriched,5.0,AF22: 30.7;Hep G2: 65.9;NTERA-2: 61.7;RH-30: 85.6
75,PTGER3,EP3,ENSG00000050628,Prostaglandin E receptor 3,1,70852353-71047808,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA010689,Uncertain,,,,Renal cancer:3.50e-4 (unfavourable),Group enriched,Group enriched,7,adipose tissue: 58.6;endometrium: 115.3;kidney: 88.3;smooth muscle: 105.2,skin: 13.9,Group enriched,5.0,ASC diff: 19.6;HAP1: 21.6;HDLM-2: 30.4;HEL: 14.0;T-47d: 68.0
76,UGT2A1,,ENSG00000173610,UDP glucuronosyltransferase family 2 member A1 complex locus,4,69588417-69653249,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA017261, HPA045108",Uncertain,,,,,Tissue enhanced,Group enriched,7,kidney: 8.1;liver: 5.5,skin: 0.9,Not detected,,
77,AMN,amnionless,ENSG00000166126,Amnion associated transmembrane protein,14,102922656-102933596,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA000817,Approved,,,,Renal cancer:9.62e-5 (favourable),Mixed,Group enriched,6,colon: 20.0;duodenum: 34.2;kidney: 29.0;small intestine: 70.6,liver: 6.7,Cell line enhanced,,CACO-2: 6.8;Hep G2: 5.6;U-698: 3.0
78,ARSF,,ENSG00000062096,Arylsulfatase F,X,3041471-3112726,Predicted membrane proteins,Evidence at protein level,HPA000549,,,Uncertain,Cytosol,,Tissue enhanced,Group enriched,6,adrenal gland: 4.0;cerebral cortex: 2.1;epididymis: 2.0;esophagus: 2.3;kidney: 8.0;skin: 6.7,liver: 0.6,Not detected,,
79,BHMT2,,ENSG00000132840,Betaine--homocysteine S-methyltransferase 2,5,79069717-79089466,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA044573,Enhanced,,,,,Group enriched,Group enriched,6,kidney: 362.7;liver: 238.5,epididymis: 46.2,Cell line enhanced,,Hep G2: 53.5;hTEC/SVTERT24-B: 46.4;U-87 MG: 18.9
80,CDC20B,FLJ37927,ENSG00000164287,Cell division cycle 20B,5,55112995-55173175,Predicted intracellular proteins,Evidence at protein level,HPA053900,Uncertain,,,,,Tissue enhanced,Group enriched,6,endometrium: 1.2;fallopian tube: 3.4;kidney: 1.2;testis: 4.9,lung: 0.4,Not detected,,
81,CRYM,DFNA40,ENSG00000103316,Crystallin mu,16,21238874-21303083,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA019086, HPA030619",Enhanced,,Supported,Cytosol,,Tissue enhanced,Group enriched,6,cerebral cortex: 51.1;heart muscle: 47.8;kidney: 28.4;prostate: 24.7;urinary bladder: 14.8,lung: 5.7,Cell line enhanced,,HEL: 9.4;RPTEC TERT1: 32.9;U-87 MG: 8.7
82,CYP4F2,,ENSG00000186115,Cytochrome P450 family 4 subfamily F member 2,19,15878023-15898120,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA014048, HPA017265, HPA058960",Supported,,,,,Tissue enriched,Group enriched,6,duodenum: 78.2;epididymis: 28.0;kidney: 39.3;liver: 84.6;small intestine: 84.3,prostate: 10.4,Cell line enhanced,,Hep G2: 2.5
83,DCXR,"DCR, KIDCR, SDR20C1",ENSG00000169738,Dicarbonyl and L-xylulose reductase,17,82035136-82037732,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA023371, HPA023863",Enhanced,,Uncertain,Nucleoli<br>Microtubules,"Renal cancer:2.13e-4 (favourable), Pancreatic cancer:4.70e-4 (favourable)",Expressed in all,Group enriched,6,epididymis: 297.5;kidney: 217.3;liver: 640.9;prostate: 137.5,adipose tissue: 56.7,Expressed in all,,
84,DNMT3L,MGC1090,ENSG00000142182,DNA methyltransferase 3 like,21,44246339-44262216,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA055234, HPA066780",Uncertain,,Approved,Nuclear speckles,,Tissue enriched,Group enriched,6,kidney: 7.2;liver: 10.4;lymph node: 2.3,spleen: 1.1,Cell line enriched,7.0,BEWO: 40.9
85,FXYD2,"ATP1G1, HOMG2, MGC12372",ENSG00000137731,FXYD domain containing ion transport regulator 2,11,117800844-117828698,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA064218, HPA068838",Supported,,Approved,Mitochondria,Renal cancer:3.23e-9 (favourable),Tissue enriched,Group enriched,6,gallbladder: 571.3;kidney: 1433.1;salivary gland: 380.4,pancreas: 134.6,Group enriched,24.0,MOLT-4: 1801.2;RPTEC TERT1: 3683.4
86,GATM,AGAT,ENSG00000171766,Glycine amidinotransferase,15,45361124-45402327,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA026077,Enhanced,,Supported,Mitochondria,Renal cancer:1.38e-4 (favourable),Expressed in all,Group enriched,6,kidney: 1904.2;liver: 1291.1;pancreas: 573.9,ovary: 195.7,Cell line enhanced,,RH-30: 190.4;U-266/70: 92.4;U-266/84: 115.1
87,HAVCR1,"CD365, HAVCR, HAVCR-1, KIM1, TIM-1, TIM1, TIMD1",ENSG00000113249,Hepatitis A virus cellular receptor 1,5,157029413-157059119,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA007173, CAB075697",Approved,,Approved,Vesicles,"Urothelial cancer:1.32e-4 (favourable), Stomach cancer:7.81e-4 (unfavourable)",Tissue enriched,Group enriched,6,colon: 4.8;kidney: 8.3;rectum: 4.1;testis: 1.7,gallbladder: 0.8,Group enriched,5.0,A549: 86.4;CACO-2: 95.7;RPTEC TERT1: 33.8
88,HNF4A,"HNF4, MODY, MODY1, NR2A1, TCF14",ENSG00000101076,Hepatocyte nuclear factor 4 alpha,20,44355700-44434596,"Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA004712, CAB019417",Enhanced,,Supported,Nucleoplasm,,Tissue enhanced,Group enriched,6,colon: 58.0;duodenum: 103.0;kidney: 44.7;liver: 51.0;rectum: 47.8;small intestine: 90.9;stomach: 21.9,gallbladder: 9.2,Group enriched,8.0,CACO-2: 126.0;Hep G2: 77.0
89,LRP2,"DBS, gp330",ENSG00000081479,LDL receptor related protein 2,2,169127109-169362685,"Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA005980, HPA064792",Enhanced,,Approved,Vesicles<br>Mitochondria,Renal cancer:3.43e-5 (favourable),Group enriched,Group enriched,6,kidney: 49.8;parathyroid gland: 155.8;thyroid gland: 37.0,breast: 14.2,Group enriched,11.0,AF22: 39.4;CACO-2: 56.2
90,PCK2,"PEPCK, PEPCK2",ENSG00000100889,"Phosphoenolpyruvate carboxykinase 2, mitochondrial",14,24094053-24110598,"Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB018734, HPA051162, HPA053502",Enhanced,,Enhanced,Mitochondria,Liver cancer:2.81e-4 (favourable),Expressed in all,Group enriched,6,duodenum: 367.6;kidney: 192.2;liver: 258.6;small intestine: 276.5,colon: 47.0,Expressed in all,,
91,PDZK1IP1,"DD96, MAP17, SPAP",ENSG00000162366,PDZK1 interacting protein 1,1,47183593-47191044,Predicted membrane proteins,Evidence at protein level,HPA014907,Enhanced,,Approved,Nuclear speckles<br>Cytosol,"Pancreatic cancer:3.45e-4 (unfavourable), Glioma:9.46e-4 (unfavourable)",Expressed in all,Group enriched,6,gallbladder: 297.8;kidney: 1052.9,esophagus: 121.2,Group enriched,5.0,EFO-21: 138.3;RPTEC TERT1: 370.1
92,PLPPR1,"FLJ20300, LPPR1, MGC26189, PRG-3",ENSG00000148123,Phospholipid phosphatase related 1,9,101028709-101325135,Predicted membrane proteins,Evidence at protein level,"HPA014760, HPA014968, HPA014979",Supported,,Supported,Nucleoplasm,Lung cancer:1.37e-4 (favourable),Group enriched,Group enriched,6,cerebral cortex: 23.8;kidney: 15.8,epididymis: 3.3,Cell line enhanced,,Hep G2: 2.1;SCLC-21H: 6.4
93,STAP1,"BRDG1, STAP-1",ENSG00000035720,Signal transducing adaptor family member 1,4,67558728-67607337,Predicted intracellular proteins,Evidence at protein level,HPA038529,Enhanced,,Uncertain,Nucleoplasm<br>Vesicles,,Tissue enriched,Group enriched,6,appendix: 23.8;kidney: 13.2;lymph node: 59.6;spleen: 26.6;tonsil: 56.3,testis: 6.1,Cell line enhanced,,Daudi: 141.5;U-698: 60.7;U-937: 22.3
94,UGT1A6,"GNT1, HLUGP, UGT1F",ENSG00000167165,UDP glucuronosyltransferase family 1 member A6,2,233691607-233773300,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB009819, HPA054065",Enhanced,,,,Liver cancer:2.89e-6 (unfavourable),Tissue enhanced,Group enriched,6,kidney: 75.4;liver: 72.4;urinary bladder: 107.9,esophagus: 15.2,Cell line enhanced,,CACO-2: 44.4;EFO-21: 75.2;HaCaT: 258.5;RT4: 119.0
95,WDR72,FLJ38736,ENSG00000166415,WD repeat domain 72,15,53513741-53762878,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA048212, HPA057410, HPA059819",Uncertain,,Approved,Vesicles,"Renal cancer:3.33e-16 (favourable), Thyroid cancer:1.80e-4 (unfavourable)",Mixed,Group enriched,6,kidney: 104.7;thyroid gland: 92.1,liver: 16.9,Cell line enhanced,,A549: 8.9;EFO-21: 5.9;NTERA-2: 5.9;RPMI-8226: 11.9;RPTEC TERT1: 8.1;U-266/70: 5.7
96,ZFAT,"KIAA1485, ZFAT1, ZNF406",ENSG00000066827,Zinc finger and AT-hook domain containing,8,134477788-134713049,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA020989, HPA063592",Enhanced,,Approved,Nucleoplasm<br>Nuclear bodies,,Expressed in all,Group enriched,6,kidney: 10.5;placenta: 44.3,testis: 4.3,Mixed,,
97,ACE2,,ENSG00000130234,Angiotensin I converting enzyme 2,X,15561033-15602148,"Enzymes, FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,"HPA000288, CAB026174",Enhanced,,,,"Renal cancer:2.12e-5 (favourable), Liver cancer:4.21e-4 (favourable)",Tissue enhanced,Group enriched,5,duodenum: 181.1;gallbladder: 100.2;kidney: 94.0;small intestine: 261.1;testis: 93.0,heart muscle: 27.9,Cell line enhanced,,HaCaT: 1.1
98,ACY1,,ENSG00000243989,Aminoacylase 1,3,51983278-51989202,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB003695, HPA036174, HPA036175",Enhanced,,,,"Renal cancer:2.93e-4 (favourable), Urothelial cancer:6.77e-4 (favourable)",Expressed in all,Group enriched,5,duodenum: 130.8;kidney: 356.0;liver: 114.9;small intestine: 103.3,parathyroid gland: 35.0,Mixed,,
99,AKR7A3,,ENSG00000162482,Aldo-keto reductase family 7 member A3,1,19282558-19289250,Predicted intracellular proteins,Evidence at protein level,HPA064638,,,Approved,Cytosol,Renal cancer:8.80e-7 (favourable),Group enriched,Group enriched,5,duodenum: 170.4;gallbladder: 38.7;kidney: 49.0;liver: 44.8;small intestine: 106.8;stomach: 70.3,colon: 15.9,Cell line enhanced,,SK-BR-3: 12.6
100,AOX1,"AO, AOH1",ENSG00000138356,Aldehyde oxidase 1,2,200585868-200677064,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA040199, HPA040215",Enhanced,,,,Renal cancer:6.05e-5 (favourable),Tissue enriched,Group enriched,5,adrenal gland: 368.8;kidney: 97.5;liver: 432.3,ovary: 56.8,Cell line enhanced,,ASC diff: 241.4;ASC TERT1: 125.7;hTERT-HME1: 56.6
101,DHDH,HUM2DD,ENSG00000104808,Dihydrodiol dehydrogenase,19,48933682-48944969,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA044131,Approved,,Approved,Nucleoplasm<br>Actin filaments,"Renal cancer:3.15e-4 (favourable), Endometrial cancer:9.91e-4 (unfavourable)",Expressed in all,Group enriched,5,duodenum: 10.2;kidney: 17.8;prostate: 5.1;small intestine: 18.6,testis: 2.5,Cell line enhanced,,SCLC-21H: 2.5
102,EMX2,,ENSG00000170370,Empty spiracles homeobox 2,10,117542444-117549546,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA003497, HPA065294",Enhanced,Supported,Approved,Nucleus,"Renal cancer:2.28e-13 (favourable), Cervical cancer:2.80e-4 (favourable)",Group enriched,Group enriched,5,"cervix, uterine: 59.5;endometrium: 114.9;epididymis: 115.2;fallopian tube: 73.0;kidney: 38.4;seminal vesicle: 65.3;smooth muscle: 59.8",cerebral cortex: 14.0,Cell line enhanced,,EFO-21: 22.1;fHDF/TERT166: 20.9;RPTEC TERT1: 19.9
103,ENPEP,"CD249, gp160",ENSG00000138792,Glutamyl aminopeptidase,4,110365733-110565285,"CD markers, Enzymes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA002821, HPA005128",Enhanced,,Approved,Endoplasmic reticulum,,Tissue enriched,Group enriched,5,duodenum: 36.5;kidney: 94.3;parathyroid gland: 160.7;small intestine: 180.3,placenta: 21.5,Cell line enhanced,,BEWO: 2.6;HEK93: 6.8;MOLT-4: 1.4
104,GSTA2,GST2,ENSG00000244067,Glutathione S-transferase alpha 2,6,52750089-52763569,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA004342, HPA048934, HPA053817",Supported,,Supported,Cytosol,Renal cancer:1.17e-4 (unfavourable),Group enriched,Group enriched,5,kidney: 651.7;liver: 986.1,gallbladder: 155.6,Group enriched,17.0,CACO-2: 19.6;Hep G2: 12.5
105,KCNJ10,"Kir1.2, Kir4.1",ENSG00000177807,Potassium voltage-gated channel subfamily J member 10,1,159998651-160070483,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,HPA078302,Enhanced,,,,,Tissue enriched,Group enriched,5,cerebral cortex: 124.7;kidney: 30.6,spleen: 14.5,Cell line enhanced,,Hep G2: 4.5;SK-MEL-30: 1.6;U-266/70: 1.6
106,KL,,ENSG00000133116,Klotho,13,33016433-33066145,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,"Renal cancer:1.29e-9 (favourable), Pancreatic cancer:4.44e-4 (favourable)",Group enriched,Group enriched,5,kidney: 136.6;parathyroid gland: 346.4,placenta: 44.1,Cell line enhanced,,HMC-1: 2.1;SK-BR-3: 3.4
107,LYG1,SALW1939,ENSG00000144214,Lysozyme g1,2,99284238-99304742,Predicted secreted proteins,Evidence at transcript level,,,,,,Renal cancer:8.44e-4 (favourable),Tissue enriched,Group enriched,5,kidney: 22.0;testis: 4.8,breast: 2.5,Mixed,,
108,MYO3B,,ENSG00000071909,Myosin IIIB,2,170178145-170655171,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA045483,Approved,,,,,Mixed,Group enriched,5,epididymis: 11.8;kidney: 4.8;parathyroid gland: 15.3;urinary bladder: 4.2,thyroid gland: 1.6,Group enriched,11.0,HDLM-2: 8.9;HEL: 7.8;RT4: 7.8
109,MYOM3,FLJ35961,ENSG00000142661,Myomesin 3,1,24056035-24112175,Predicted intracellular proteins,Evidence at protein level,"HPA028132, HPA029752",Uncertain,,Approved,Vesicles,Renal cancer:4.28e-6 (favourable),Tissue enhanced,Group enriched,5,heart muscle: 69.9;kidney: 31.8;skeletal muscle: 86.5,testis: 12.1,Cell line enhanced,,A549: 4.2;Hep G2: 12.2
110,PAX2,,ENSG00000075891,Paired box 2,10,100735603-100829941,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at protein level,"CAB013024, HPA047704, HPA070751",Enhanced,,Supported,Nucleoli<br>Golgi apparatus,Endometrial cancer:4.56e-4 (unfavourable),Group enriched,Group enriched,5,epididymis: 37.1;fallopian tube: 19.0;kidney: 25.3;seminal vesicle: 20.0,"cervix, uterine: 4.9",Group enriched,8.0,AN3-CA: 16.6;EFO-21: 23.1;RPTEC TERT1: 13.3
111,PKHD1,"ARPKD, FCYT, TIGM1",ENSG00000170927,Polycystic kidney and hepatic disease 1 (autosomal recessive),6,51615300-52087625,"Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA031227,Approved,,,,Renal cancer:9.74e-8 (favourable),Group enriched,Group enriched,5,epididymis: 5.7;kidney: 15.3,pancreas: 1.9,Cell line enriched,7.0,RPTEC TERT1: 8.1
112,SLC23A1,"SLC23A2, SVCT1, YSPL3",ENSG00000170482,Solute carrier family 23 member 1,5,139367196-139384553,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA047612,Enhanced,,,,,Group enriched,Group enriched,5,duodenum: 26.7;fallopian tube: 86.2;kidney: 41.9;small intestine: 72.0,liver: 10.7,Cell line enhanced,,CACO-2: 7.7;HDLM-2: 7.6;Hep G2: 9.2;Karpas-707: 7.8;RPMI-8226: 7.6;U-266/70: 12.7
113,SLC27A2,"ACSVL1, FACVL1, FATP2, hFACVL1, HsT17226, VLACS, VLCS",ENSG00000140284,Solute carrier family 27 member 2,15,50182196-50236395,"Enzymes, Predicted membrane proteins, Transporters",Evidence at protein level,HPA026089,Enhanced,,,,"Renal cancer:7.48e-6 (favourable), Urothelial cancer:6.40e-4 (favourable)",Tissue enhanced,Group enriched,5,epididymis: 80.1;kidney: 162.3;liver: 145.5,placenta: 24.7,Cell line enhanced,,HaCaT: 78.4;HL-60: 52.3;SCLC-21H: 47.4
114,SLC47A2,"FLJ31196, MATE2, MATE2-K",ENSG00000180638,Solute carrier family 47 member 2,17,19678288-19718979,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,Glioma:7.41e-4 (unfavourable),Tissue enhanced,Group enriched,5,fallopian tube: 16.5;kidney: 49.3,epididymis: 6.4,Cell line enhanced,,hTCEpi: 1.5
115,SLC5A11,"KST1, SGLT6, SMIT2",ENSG00000158865,Solute carrier family 5 member 11,16,24845841-24911628,Predicted membrane proteins,Evidence at protein level,HPA035331,Uncertain,,Approved,Nucleus<br>Cytosol,,Mixed,Group enriched,5,cerebral cortex: 10.5;duodenum: 6.6;kidney: 6.1;small intestine: 15.2,breast: 1.7,Cell line enhanced,,BEWO: 1.7;Hep G2: 11.2;Karpas-707: 3.2
116,SSC4D,"S4D-SRCRB, SRCRB-S4D, SRCRB4D",ENSG00000146700,Scavenger receptor cysteine rich family member with 4 domains,7,76389334-76409695,Predicted secreted proteins,Evidence at transcript level,HPA062611,Uncertain,,,,"Endometrial cancer:2.83e-6 (unfavourable), Renal cancer:4.71e-4 (unfavourable), Glioma:6.31e-4 (unfavourable)",Mixed,Group enriched,5,kidney: 1.4;parathyroid gland: 4.2;thyroid gland: 2.0,"cervix, uterine: 0.5",Group enriched,12.0,EFO-21: 6.3;Hep G2: 6.5;U-2 OS: 27.2
117,TAL2,bHLHa19,ENSG00000186051,TAL bHLH transcription factor 2,9,105662457-105663112,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA030886,Uncertain,,Approved,Cytosol,Renal cancer:2.69e-4 (favourable),Tissue enhanced,Group enriched,5,kidney: 3.5;skeletal muscle: 4.8,epididymis: 0.8,Cell line enhanced,,HAP1: 3.1;K-562: 7.5
118,TMEM132E,DFNB99,ENSG00000181291,Transmembrane protein 132E,17,34580749-34639318,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA070608,Approved,,,,Renal cancer:1.55e-4 (unfavourable),Group enriched,Group enriched,5,cerebral cortex: 4.8;duodenum: 1.7;kidney: 3.2;small intestine: 1.0;testis: 1.5,"cervix, uterine: 0.4",Cell line enriched,7.0,RPMI-8226: 31.6
